Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

Abd-Elsalam, 2020
 
NCT04353336
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
97/97 inconclusive 19%
ARCHAIC -hydroxychloroquine, 2020
 
NL8490
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
9/6 inconclusive 360%
CCAP-1, 2020
 
NCT04345289
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
-/- inconclusive 0%
Chen, 2020
 
NCT04384380
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
21/12 inconclusive -40%
Duke university HCQ, 2020
 
NCT04335552
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
4/2 no results
Gonzalez_HCQ, 2020
 
NCT04391127
RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
33/37 inconclusive -60% -28%
HAHPS, 2020
 
NCT04329832
RCThydroxychloroquineazithromycinCOVID 19 hospitalizedsome concern
42/43 inconclusive 540%
HYCOVID, 2020
 
NCT04325893
RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
124/123 inconclusive -41% 11%
NO COVID-19 (Lyngbakken), 2020
 
NCT04316377
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
27/26 inconclusive -4%
OAHU-COVID19, 2020
 
NCT04345692
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
10/6 inconclusive 158%
ORCHID, 2020
 
NCT04332991
RCThydroxychloroquineplaceboCOVID 19 hospitalizedlow
242/237 inconclusive 6% 2% 12%
PROTECT B, 2020
 
NCT04338698
RCThydroxychloroquineoseltamivirCOVID 19 hospitalizedNA
-/- inconclusive -44%
RECOVERY, 2020
 
NCT04381936
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
1561/3155 safety concern 8% 13%
SOLIDARITY (WHO study) HCQ, 2020
 
NCT04315948
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
947/906 inconclusive 17% 10%
Tang, 2020
 
ChiCTR2000029868
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedhigh
75/75 safety concern 0%
TEACH, 2020
 
NCT04369742
RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
67/61 inconclusive 6%
Arshad (HCQ), 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
1202/409 suggested -59%
Belgian Collaborative Group on COVID-19, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
4542/3533 suggested -28%
Geleris, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
811/565 inconclusive 4% 4%
Magagnoli (HC), 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
97/158 safety concern safety concern145%
Novales, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
123/43 suggested -84%
Paccoud, 2020 OBShydroxychloroquinestandard of careCOVID 19 hospitalizedserious
38/46 inconclusive -10%
Sbidian (HCQ alone), 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
623/3792 safety concern 23%
Singh, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
-/- inconclusive 17%

COVID 19 all comers meta-analysis

ChiCTR2000030054-HCQ (Chen), 2020
 
ChiCTR2000030054
RCThydroxychloroquinestandard of careCOVID 19 all comershigh
18/12 inconclusive -31%
Gautret et al., 2020 NRahydroxychloroquinecontrolCOVID 19 all comersserious
20/16 suggested

COVID-19 mild to moderate meta-analysis

Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020
 
NCT04322123
RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
221/227 safety concern 42%
HC-nCoV (Shanghai), 2020
 
NCT04261517
RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
15/15 inconclusive 0%
NCT04333654, 2020
 
NCT04333654
RCThydroxychloroquinestandard of careCOVID-19 mild to moderateNA
-/- inconclusive -40%
Zhaowei Chen, 2020
 
ChiCTR2000029559
RCThydroxychloroquinecontrolCOVID-19 mild to moderatehigh
31/31 inconclusive 0%
Zhaowei Chen, 2020
 
ChiCTR2000029559
RCThydroxychloroquinestandard of careCOVID-19 mild to moderatehigh
31/31 suggested
Min, 2020 OBShydroxychloroquinecontrolCOVID-19 mild to moderateNA
20/20 inconclusive

COVID-19 severe or critically meta-analysis

HYDRA, 2020
 
NCT04315896
RCThydroxychloroquineplaceboCOVID-19 severe or criticallyNA
75/77 inconclusive -1%
REMAP-CAP-HCQ, 2020
 
NCT02735707
RCThydroxychloroquinestandard of careCOVID-19 severe or criticallyNA
61/81 inconclusive 4%
Mahevas, 2020 OBShydroxychloroquinestandard of careCOVID-19 severe or criticallyserious
84/97 inconclusive -35%
Yu, 2020 OBShydroxychloroquinecontrolCOVID-19 severe or criticallycritical
48/520 suggested -61%

COVID 19 outpatients meta-analysis

PATCH Cohort 1 (Amaravadi), 2021
 
NCT04329923
RCThydroxychloroquinestandard of careCOVID 19 outpatientssome concern
15/13 inconclusive -12%
BCN PEP-CoV-2-Research group (Mitja et al. Clin Infect Dis), 2020
 
NCT04304053
RCThydroxychloroquinestandard of careCOVID 19 outpatientssome concern
137/157 safety concern 14%
BCN PEP-CoV-2-Study 2 (Mitja Lancet), 2020
 
NCT04304053
RCThydroxychloroquinestandard of careCOVID 19 outpatientssome concern
142/165 inconclusive 15%
COMIHY, 2020
 
NCT04340544
RCThydroxychloroquinestandard of careCOVID 19 outpatientsNA
-/- inconclusive 0%
COVID-PEP Severity (Skipper), 2020
 
NCT04308668
RCThydroxychloroquinecontrolCOVID 19 outpatientssome concern
244/247 no results
COVID-PEP Severity (Skipper), 2020
 
NCT04308668
RCThydroxychloroquineplaceboCOVID 19 outpatientssome concern
244/247 safety concern 1% 32%
Q-PROTECT -HCQ alone, 2020
 
NCT04349592
RCThydroxychloroquineplaceboCOVID 19 outpatientsNA
152/152 inconclusive
Agusti, 2020 OBShydroxychloroquinecontrolCOVID 19 outpatientsNA
87/55 inconclusive -33%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).